alpha-MSH analogue comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-10-14. Numbers and descriptions here follow the published literature rather than marketing material.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Reversed-phase high-performance liquid chromatography is the routine method for purity assessment. Peptides absorb near 214 nm because of the peptide bond, and a gradient of acetonitrile in water separates the intact peptide from deletion sequences, oxidised products, and earlier-eluting fragments at neutral pH. Electrospray ionisation mass spectrometry provides an orthogonal check: the measured mass must agree with the theoretical value. Amino acid analysis and peptide mapping confirm structure but are used less often. Reference standards remain scarce because the peptide is not described in any pharmacopoeia.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Spontaneous and unpredictable pain at any time, and specific causal factors cannot be identified Patient may complain of sharp lingering pains that last longer than 30 seconds, even after removal of stimulus Possible referred pain Pain may increase with changes of posture, e.g. from lying down to standing. Analgesics tend to be ineffective. No pain on percussion because the bacteria are not present in the peri-apical region. Key characteristics of asymptomatic irreversible pulpitis include:
Enishi (Hokkaido) Teishu (Honshu) Iyo (Shikoku) Tsukushi (Kyushu) Ryugu (Okinawa) Like every other nation in the world, Yamato has its own Agents of the Four Seasons, each of whom has the duty to manifest their season in every part of the land. The Agents of Spring and Summer begin their journey on the island of Ryugu then move north, while the Agents of Autumn and Winter begin their journey on the island of Enishi, then head south. The role of "Agent" is bestowed by the deities of the seasons based on the physical, mental and spiritual eligibility of a blood descendant of the first Agent, and the chosen individual cannot in any way oppose their destiny. The bestowal occurs when the previous Agent dies or ceases to be eligible for the role. It is possible for an Agent, due to insufficient preparation or drastic events, to be unable to manifest their season, consequently extending the duration of the previous one. This is the case of the Agent of Spring, Hinagiku Kayo, a 16-year-old girl who was kidnapped by the Insurgents at the age of just 6. As a result, spring hasn't manifested in Yamato for 10 years, and winter, instead of lasting 3 months like the other seasons, has lasted 6 months during this period of time. However, the young Hinagiku has made her return and is now preparing to bring her season back to the nation, accompanied by her guard, Sakura Himedaka. It all begins on February 10th of the year 20 of the Reimei era, on the island of Ryugu.
Day of Defeat is a class-based multiplayer first-person shooter video game set in the European theatre of World War II on the Western front. Originally a modification of the 1998 game Half-Life, the rights of the modification were purchased by Valve and released as a full retail title in 2003. Set in the midst of World War II, Day of Defeat includes no single-player campaign, with focus left only on the game's multiplayer aspects. The game favors teamwork and features objective-based gameplay in combination with its system of classes. Maps are primarily made up of narrow paths, all of which typically lead to a few key locations. An official remake of the game, Day of Defeat: Source, was released by Valve in 2005.
Sources: en.wikipedia.org
Abiotic factors that can damage plants include heat, freezing, flooding, lightning strikes, ozone gas, and pollutant chemicals. Heat can kill any plant, given a sufficient temperature. Alpine plants tend to die at around 47 Celsius; temperate plants at around 51 Celsius; and tropical plants at nearly 58 Celsius: but there is some overlap depending on species. Similarly among cereal crops, temperate barley and oat die at around 49 Celsius, but tropical maize at 55 Celsius. Freezing affects plants variously, according to each species' ability to resist frost damage. Many forbs, including many garden flowers, are tender with little tolerance to frost, and die or are seriously damaged when frozen. Many woody plants are able to supercool, with tough buds and stems containing molecules that lower the freezing point or help to prevent the nucleation of ice crystals, and cell walls that mechanically protect cells against freezing. Flooding of soil quickly kills or injures many plants. The leaves become yellow (chlorosis) and die, progressively up the stem, within about five days after the roots are flooded. The roots lose the ability to absorb water and nutrients. Lightning strikes kill or injure plants, from root crops like beet and potato, which are instantly cooked in the ground, to trees such as coconut, through effects such as sudden heat and pressure shock waves created when water inside the plant flashes to steam. This can rupture stems and scorch any plant parts.
In early February, the North Korean government took severe measures to block the spread of COVID-19. Rodong Sinmun, the Workers' Party of Korea newspaper, reported that the customs officials at the port of Nampo were performing disinfection activities, including placing imported goods in quarantine. All international flights and railway services were suspended in early February, and connections by sea and road were largely closed over the following weeks. In February, wearing face masks was obligatory, and visiting public places such as restaurants was forbidden. Ski resorts and spas were closed, and military parades, marathons, and other public events were cancelled. Schools were closed throughout the country; university students in Pyongyang from elsewhere in the country were confined to their dormitories. Although South Korean media reported the epidemic had spread to North Korea, the WHO said there were no indications of cases there. On 18 February, Rodong Sinmun, the official newspaper of North Korea's ruling party, quoted a public health official reiterating that there had been "no confirmed case of the new coronavirus so far". The WHO prioritised aid for North Korea, including the shipment of protective equipment and supplies. The Daily NK reported information from an informant inside North Korea's military on 9 March, stating that 180 soldiers had died in January and February from complications of "high fevers stemming from pneumonia, tuberculosis, asthma or colds", while about 3,700 soldiers were under quarantine.
=== Drug discovery problems === In September 2005, Dr. Reddy's spun off its drug discovery and research wing into a separate company called Perlecan Pharma Private Limited. At the time, this was hailed as an innovative move, but in 2008, the company had to be wound down due to funding constraints. Dr. Reddy's was the first Indian pharma company to attempt such an effort to de-couple risk of drug discovery from the parent company by creating a separate company with an external source of funding. Perlecan Pharma was partially funded by ICICI Venture Capital and Citigroup Venture International, both of which held a 43% stake in Perlecan for an estimated $22.5 million. However, the company was forced to buy back the Perlecan shares from ICICI and Citigroup due to doubts regarding the commercial viability of the drug candidates that were in Perlecan's pipeline. At that point, Perlecan became a wholly owned subsidiary. In the board meeting of 23 October 2008, the company chose to amalgamate/absorb Perlecan, thereby making it an in-house research facility, as it was before 2005. In 2009, the company did a U-turn and has handed over discovery research and related intellectual property to its Bangalore-based subsidiary, with the possibility of spinning it off as a different entity altogether. "The company may be hoping to find a strategic partner in the future to share the risks and research funding."
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
Low temperature slows hydrolysis and oxidation, the two main routes by which the peptide backbone and side chains are modified. A lyophilised powder stored at −20 °C is more stable than one kept at room temperature, and once the material is dissolved the degradation rate rises, making refrigeration more important.